Northern Trust Corporation Common Stock vs Smith & Nephew plc — how do they compare? Northern Trust Corporation Common Stock trades at $162.48 (market cap $29.76B), while Smith & Nephew plc trades at $28.6 (market cap $11.65B). The key difference: Northern Trust Corporation Common Stock is far larger — about 2.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals — on Pluang, investors hold Northern Trust Corporation Common Stock for 0 Days and Smith & Nephew plc for 121 Days on average.
| NTRS | SNN | |
|---|---|---|
Market Cap | $29.76B | $11.65B |
Volume | 1,427,762 | 860,347 |
Sector | Financials | Health |
52-Week High | $191.47 | $37.17 |
52-Week Low | $122.72 | $26.42 |
Typical Hold Time | 0 Days | 121 Days |
Enterprise Value | -$6.24B | $14.68B |
Dividend Yield | 2.02% | 2.85% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith+Nephew (SNN) trades at $27.86, near its 52-week low, with a mixed technical signal but strong fundamental growth. Revenue and net income have increased steadily, with a 10.08% net margin in 2025, while valuation ratios like a P/E of 18.97 appear reasonable. Recent product launches, such as the EVOS PELVIC System, highlight ongoing innovation, though the stock faces bearish moving average signals and a high short-term RSI.
The outlook is cautiously optimistic given solid earnings beats and profitability, but risks include competitive pressures and recent CFO departure. Analyst sentiment is neutral with a majority hold rating, suggesting limited near-term upside amid execution concerns. Investors should weigh strong cash flow generation against technical weakness and market sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Northern Trust Corporation is a financial holding company that provides asset servicing, asset management, wealth management, and banking services through its Asset Servicing and Wealth Management segments. It serves corporations, institutions, and affluent individuals across US and international markets.
Read more on NTRS →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →